SCD-684
Ophthalmic inflammation
Pre-clinicalActive
Key Facts
About SPARC
SPARC is a specialized research and development arm that emerged from Sun Pharmaceutical Industries, concentrating on innovative drug delivery technologies and new molecular entities. The company has built a pipeline of novel formulations and new chemical entities targeting complex therapeutic areas with high unmet medical needs. Its strategic focus includes developing non-infringing, patent-protected products that offer significant clinical advantages over existing treatments. SPARC's valuation reflects its potential to deliver breakthrough innovations through its research platforms.
View full company profileTherapeutic Areas
Other Ophthalmic inflammation Drugs
| Drug | Company | Phase |
|---|---|---|
| Lotemax (loteprednol etabonate) | Bausch Health | Approved |